Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55


Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.

Kato T, Komiya A, Yuasa J, Kaga K, Kaga M, Kojima S, Naya Y, Isaka S.

Oncol Lett. 2018 Feb;15(2):2669-2672. doi: 10.3892/ol.2017.7628. Epub 2017 Dec 14.


Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma.

Yamada Y, Arai T, Sugawara S, Okato A, Kato M, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Cancer Sci. 2018 Feb 8. doi: 10.1111/cas.13526. [Epub ahead of print]


Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.

Yamada Y, Nishikawa R, Kato M, Okato A, Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N.

J Hum Genet. 2018 Feb;63(2):195-205. doi: 10.1038/s10038-017-0371-1. Epub 2017 Dec 1.


Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma.

Okato A, Arai T, Yamada Y, Sugawara S, Koshizuka K, Fujimura L, Kurozumi A, Kato M, Kojima S, Naya Y, Ichikawa T, Seki N.

Int J Mol Sci. 2017 Sep 13;18(9). pii: E1969. doi: 10.3390/ijms18091969.


Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.

Arai T, Okato A, Kojima S, Idichi T, Koshizuka K, Kurozumi A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N.

Cancer Sci. 2017 Oct;108(10):2088-2101. doi: 10.1111/cas.13331. Epub 2017 Aug 19.


Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.

Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N.

Br J Cancer. 2017 Jul 25;117(3):409-420. doi: 10.1038/bjc.2017.191. Epub 2017 Jun 22.


Dual strands of pre-miR‑150 (miR‑150‑5p and miR‑150‑3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer.

Okato A, Arai T, Kojima S, Koshizuka K, Osako Y, Idichi T, Kurozumi A, Goto Y, Kato M, Naya Y, Ichikawa T, Seki N.

Int J Oncol. 2017 Jul;51(1):245-256. doi: 10.3892/ijo.2017.4008. Epub 2017 May 17.


Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer.

Masuda H, Kaga K, Inahara M, Araki K, Kojima S, Naya Y, Takano M.

Urol Case Rep. 2017 Apr 26;13:63-65. doi: 10.1016/j.eucr.2016.11.019. eCollection 2017 Jul.


Usefulness of R.E.N.A.L Nephrometry Scoring System and Centrality Index Score for Predicting Outcome of Laparoscopic Partial Nephrectomy.

Sugiura M, Suyama T, Kanesaka M, Fujimoto A, Hou K, Araki K, Masuda H, Kojima S, Naya Y.

J Laparoendosc Adv Surg Tech A. 2016 Oct;26(10):784-788. Epub 2016 Jul 19.


The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.

Goto Y, Kurozumi A, Nohata N, Kojima S, Matsushita R, Yoshino H, Yamazaki K, Ishida Y, Ichikawa T, Naya Y, Seki N.

Oncotarget. 2016 Sep 13;7(37):59070-59086. doi: 10.18632/oncotarget.10887.



Kojima S, Seki N.

Nihon Rinsho. 2016 May 20;74 Suppl 3:201-4. Japanese. No abstract available.


The roles of microRNAs in the progression of castration-resistant prostate cancer.

Kojima S, Goto Y, Naya Y.

J Hum Genet. 2017 Jan;62(1):25-31. doi: 10.1038/jhg.2016.69. Epub 2016 Jun 9. Review.


Mobile spinal enterogenous cyst resulting in intermittent paraplegia in a child: case report.

Kojima S, Yoshimura J, Takao T, Tamura T, Nishiyama K, Maruyama S, Suda M, Fujii Y.

J Neurosurg Pediatr. 2016 Oct;18(4):448-451. Epub 2016 Jun 3.


Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer.

Okato A, Goto Y, Kurozumi A, Kato M, Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T, Seki N.

Int J Oncol. 2016 Jul;49(1):111-22. doi: 10.3892/ijo.2016.3522. Epub 2016 May 16.


Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer.

Goto Y, Kojima S, Kurozumi A, Kato M, Okato A, Matsushita R, Ichikawa T, Seki N.

Br J Cancer. 2016 May 10;114(10):1135-44. doi: 10.1038/bjc.2016.95. Epub 2016 Apr 12.


Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells.

Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Takahashi J, Kojima S, Yamashita A, Tomio K, Nagamatsu T, Wada-Hiraike O, Oda K, Osuga Y, Fujii T.

Int J Oncol. 2016 Feb;48(2):829-35. doi: 10.3892/ijo.2015.3283. Epub 2015 Dec 9.


Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients.

Tsuruga T, Fujimoto A, Kawana K, Mori M, Hasumi Y, Kino N, Tomio K, Miura S, Tanikawa M, Sone K, Miyamoto Y, Ikeda Y, Kojima S, Adachi K, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Nakagawa S, Horie K, Yasugi T, Yokota H, Osuga Y, Fujii T.

Int J Clin Oncol. 2016 Apr;21(2):359-366. doi: 10.1007/s10147-015-0907-3. Epub 2015 Oct 5.


MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.

Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M, Naya Y, Ichikawa T, Seki N.

Br J Cancer. 2015 Sep 29;113(7):1055-65. doi: 10.1038/bjc.2015.300. Epub 2015 Sep 1.


MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer.

Nishikawa R, Goto Y, Kurozumi A, Matsushita R, Enokida H, Kojima S, Naya Y, Nakagawa M, Ichikawa T, Seki N.

Int J Urol. 2015 Sep;22(9):867-77. doi: 10.1111/iju.12829. Epub 2015 Jun 7.


Supplemental Content

Loading ...
Support Center